このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

治療歴のある局所進行性または転移性放射性ヨウ素抵抗性 BRAFV600E 変異陽性分化型甲状腺がん患者におけるダブラフェニブとトラメチニブの有効性と安全性に関する研究

2026年9月17日 更新者:Novartis Pharmaceuticals

治療歴のある局所進行性または転移性の放射性ヨウ素抵抗性BRAFV600E変異陽性甲状腺分化がん(DTC)患者におけるダブラフェニブとトラメチニブの併用の有効性と安全性を評価する無作為化二重盲検プラセボ対照第III相試験

The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.

調査の概要

詳細な説明

This is a global, multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that is positive for the BRAF V600E mutation, refractory to radioactive iodine (RAI), and has progressed following prior vascular endothelial growth factor receptor (VEGFR) targeted therapy.

After eligibility assessment, patients will be randomized in a 2:1 ratio to receive either dabrafenib plus trametinib or placebo. Patients will be stratified by the number of prior VEGFR targeted therapies (one versus two) and prior lenvatinib treatment (yes versus no).

The scientific objective guiding the primary estimand is based on progression-free survival (PFS) as per blinded independent review committee (BIRC) assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

This study will enroll approximately 150 patients.

Patients randomized to the placebo arm who experience disease progression as per RECIST 1.1 confirmed by BIRC and meet eligibility criteria will have the option to cross over to the open-label combination of dabrafenib plus trametinib.

Treatment may continue beyond RECIST 1.1 disease progression (confirmed by BIRC) if, in the investigator's judgment, there is evidence of clinical benefit and the patient wishes to remain on study treatment. In cases where there is a discrepancy between local site determination and BIRC (for example, disease progression determined locally but not by BIRC), the patient should not be discontinued from study treatment until progression is confirmed by BIRC or, at a minimum, until one additional tumor assessment has been completed, provided this is clinically acceptable.

After treatment discontinuation, all patients will be followed for safety and efficacy evaluations during the post-treatment follow-up period. Subsequently, patient status will be collected every 12 weeks as part of survival follow-up.

This study is ongoing, and enrollment was completed on 09-May-2024. The primary analysis was performed after all patients had either completed at least 16 weeks of treatment or discontinued early, and after approximately 95 PFS events had occurred.

研究の種類

介入

入学 (実際)

153

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University Med School
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital
    • Buenos Aires
      • CABA、Buenos Aires、アルゼンチン、C1417DTB
        • Novartis Investigative Site
      • Chennai、インド、600020
        • Novartis Investigative Site
    • Haryana
      • Hisar、Haryana、インド、125005
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、インド、110029
        • Novartis Investigative Site
    • Alberta
      • Edmonton、Alberta、カナダ、T6G 1Z2
        • Novartis Investigative Site
    • Ontario
      • London、Ontario、カナダ、N6A 5W9
        • Novartis Investigative Site
    • Fatih
      • Istanbul、Fatih、トルコ(Türkiye)、34098
        • Novartis Investigative Site
    • Merkez
      • Edirne、Merkez、トルコ(Türkiye)、22030
        • Novartis Investigative Site
    • Yenimahalle
      • Ankara、Yenimahalle、トルコ(Türkiye)、06500
        • Novartis Investigative Site
    • Yuregir
      • Adana、Yuregir、トルコ(Türkiye)、01250
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janiero、Rio de Janeiro、ブラジル、20231-050
        • Novartis Investigative Site
    • Santa Catarina
      • Blumenau、Santa Catarina、ブラジル、89015-200
        • Novartis Investigative Site
    • São Paulo
      • São Paulo、São Paulo、ブラジル、01246-000
        • Novartis Investigative Site
      • Hanoi、ベトナム、100000
        • Novartis Investigative Site
      • Kuala Lumpur、マレーシア、59100
        • Novartis Investigative Site
    • Pulau Pinang
      • George Town、Pulau Pinang、マレーシア、10450
        • Novartis Investigative Site
    • Sarawak
      • Kuching、Sarawak、マレーシア、93586
        • Novartis Investigative Site
      • Beijing、中国、100730
        • Novartis Investigative Site
      • Beijing、中国、100036
        • Novartis Investigative Site
      • Guangzhou、中国、510060
        • Novartis Investigative Site
      • Shanghai、中国、200233
        • Novartis Investigative Site
      • Tianjin、中国、300052
        • Novartis Investigative Site
      • Tianjin、中国、300480
        • Novartis Investigative Site
    • Fujian
      • Fuzhou、Fujian、中国、350014
        • Novartis Investigative Site
    • Henan
      • Zhengzhou、Henan、中国、450008
        • Novartis Investigative Site
    • Hubei
      • Wuhan、Hubei、中国、430022
        • Novartis Investigative Site
    • Hunan
      • Changsha、Hunan、中国、410013
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing、Jiangsu、中国、210006
        • Novartis Investigative Site
      • Nanjing、Jiangsu、中国、210009
        • Novartis Investigative Site
      • Xuzhou、Jiangsu、中国、221003
        • Novartis Investigative Site
    • Jilin
      • Changchun、Jilin、中国、130033
        • Novartis Investigative Site
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • Novartis Investigative Site
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300121
        • Novartis Investigative Site
      • Tainan、台湾、704302
        • Novartis Investigative Site
      • Taipei、台湾、10002
        • Novartis Investigative Site
      • Seoul、韓国、03080
        • Novartis Investigative Site
      • Seoul、韓国、05505
        • Novartis Investigative Site
      • Seoul、韓国、06351
        • Novartis Investigative Site
      • Seoul、韓国、06591
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~99年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  • Signed informed consent
  • Male or female ≥ 18 years of age at time of informed consent
  • Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid carcinoma
  • Radioactive-iodine refractory disease
  • BRAF V600E mutation-positive tumor sample as per central laboratory result
  • Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapies
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • At least one measurable lesion as defined by RECIST v1.1.

Key Exclusion Criteria:

  • Anaplastic or medullary carcinoma of the thyroid
  • Previous treatment with a BRAF inhibitor and/or a MEK inhibitor
  • Concomitant RET Fusion-Positive Thyroid Cancer
  • Treatment with any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization
  • Treatment with any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
  • Treatment with radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
  • A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy

Other inclusion/exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dabrafenib plus Trametinib

Eligible participants will receive Dabrafenib 150 mg twice a day (BID) and Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

Dabrafenib 150 mg capsule administered orally twice a day (BID)

他の名前:
  • DRB436

Trametinib 2 mg tablet administered once a day (QD)

他の名前:
  • TMT212
プラセボコンパレーター:Dabrafenib Placebo plus Trametinib Placebo

Eligible participants will receive matching placebo for Dabrafenib 150 mg twice a day (BID) and matching placebo for Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

matching placebo tablet for Trametinib 2 mg will be administered orally once a day (QD)

matching placebo capsule for Dabrafenib 150 mg will be administered orally twice a day (BID)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression Free Survival (PFS)
時間枠:From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

Progression Free Survival (PFS) was defined as the time from the date of randomization to the date of the first documented progression according to RECIST 1.1 based on Blinded Independent Review Committee (BIRC) assessment, or death due to any cause.

The primary analysis was conducted after all patients had either completed a minimum of 16 weeks of treatment or discontinued earlier, and following the occurrence of approximately 95 PFS events (Data cut-off date for the primary analysis was 22 January 2025).

From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Response Rate (ORR)
時間枠:From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)

Overall Response Rate (ORR) was defined as the proportion of participants who had a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1.

From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)
Overall Survival (OS)
時間枠:From randomization to death assessed up to approximately 5 years

Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.

From randomization to death assessed up to approximately 5 years
Duration of Response (DOR)
時間枠:From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)

Duration of Response (DOR) applied only to patients whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1. The start date was defined as the date of the first documented confirmed CR or PR, and the end date corresponded to the date of the first documented confirmed progression or death from any cause. Patients who remained without progression or death from any cause were censored at the date of their last adequate tumor assessment prior to the initiation of any new antineoplastic therapy.

From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Throughout study completion, an average 5 years

The distribution of adverse events will be conducted through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study will be defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose, or events that are present prior to the first dose and increase in severity based on preferred term within 30 days following the last dose.

Throughout study completion, an average 5 years
Number of Participants With Trametinib Associated Serous Retinopathy Ocular Events
時間枠:Up to approximately 3 years

Analysis of the optical coherence tomography data was performed to assess the incidence, type, and severity of trametinib-associated serous retinopathy ocular events, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grading system: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death related to adverse event).

Up to approximately 3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年11月15日

一次修了 (実際)

2025年1月22日

研究の完了 (推定)

2027年5月25日

試験登録日

最初に提出

2021年6月22日

QC基準を満たした最初の提出物

2021年6月22日

最初の投稿 (実際)

2021年6月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月17日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する